Answers are grounded in this paper and cite their sources.
Randomized trial evaluates efficacy and safety of nucresiran in patients with hereditary transthyretin amyloidosis with polyneuropathy, suggesting impactful treatment options.
Describe the rationale and design of TRITON-PN, a phase 3, global, open-label, randomized study, evaluating the efficacy and safety of nucresiran in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
No takes yet. Share an insight, caveat, or question.
Obici et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: